Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02482935 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02482935 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants.
The verdict
NCT02482935, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the amount of abemaciclib that reaches the blood stream and how long the body takes to get rid of it when given with and without food. In addition, the safety and tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. The study will last about 43 days for each participant, not including screening.
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02482935
The ClinicalTrials.gov registry entry for NCT02482935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT02482935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02482935 about?
NCT02482935 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food". The purpose of this study is to evaluate the amount of abemaciclib that reaches the blood stream and how long the body takes to get rid of it when given with and without food. In addition, the safety and tolerability of the study drug will be evaluated. Information about any side effects that may oc...
What is the current status of trial NCT02482935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02482935?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT02482935?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.